News

Microlytic ApS announce that the company has secured USD 3.5 million in additional venture financing to expand sales and production operations in the Structural Biology sector.

Companies will collaborate to bring next generation three dimensional (3D) cell culture products to market in 2012. The two UK companies develop cell culture systems that bridge the current gap between 2D in-vitro cell culture and animal models.

Company has further expanded its presence in the USA by forming a new subsidiary, SAW Instruments USA, LLC, and recruiting a full time Field Application Scientist based in Boston, MA.

Carl-Johan Ivarsson, Qlucore, comments on the reducing necessity for animal models in today’s drug development industry, as research moves more towards in vitro analysis.

A new approach to data analysis is helping researchers at Cincinnati Children's Hospital Medical Center to unravel the mysteries of human disease, says Carl-Johan Ivarsson, President of Qlucore.

Breakthrough proteomic technology now available to pharmaceutical companies and academic research groups looking to discover and validate protein biomarkers for diverse applications.

Company received an NIH grant to develop an innovative test to determine an individual's stress level measuring the stress hormone Cortisol.

Immunovative Therapies, Ltd. has retained the services of Andra E. Miller, Ph.D. and Holly M. Scott of Biologics Consulting Group, Inc. to provide Immunovative with in-depth assistance and compliance with U.S. Food FDA regulations and requirements with respect to GCP and GMP.

In this study, researchers from Emory University, have used “top-down” metabolic profiling to determine the spectrum of metabolites present in liver mitochondria.

Researchers also spied on Dr Snyder's immune system and watched it battle viral infections.